JPH11506904A - Ｒａｇｅ腫瘍拒絶抗原 - Google Patents

Ｒａｇｅ腫瘍拒絶抗原

Info

Publication number
JPH11506904A
JPH11506904A JP8528658A JP52865896A JPH11506904A JP H11506904 A JPH11506904 A JP H11506904A JP 8528658 A JP8528658 A JP 8528658A JP 52865896 A JP52865896 A JP 52865896A JP H11506904 A JPH11506904 A JP H11506904A
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
rage
tumor rejection
rejection antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP8528658A
Other languages
English (en)
Japanese (ja)
Inventor
ゴーグレ，ベアトリッス
ヴェン・デン・エインデ，ブノア
シュリール，ペーター
ブロアーンストリン，ナタリー
ブン−ファレール，ティエリー
Original Assignee
ルートヴィヒ・インスティチュート・フォー・キャンサー・リサーチ
ライデン・ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/530,569 external-priority patent/US5939526A/en
Application filed by ルートヴィヒ・インスティチュート・フォー・キャンサー・リサーチ, ライデン・ユニバーシティ filed Critical ルートヴィヒ・インスティチュート・フォー・キャンサー・リサーチ
Publication of JPH11506904A publication Critical patent/JPH11506904A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP8528658A 1995-03-21 1996-03-21 Ｒａｇｅ腫瘍拒絶抗原 Ceased JPH11506904A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40801595A 1995-03-21 1995-03-21
US08/530,569 1995-09-20
US08/530,569 US5939526A (en) 1995-03-21 1995-09-20 Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof
US08/408,015 1995-09-20
PCT/US1996/004037 WO1996029409A2 (fr) 1995-03-21 1996-03-21 Antigenes de rejet de tumeurs de la famille rage

Publications (1)

Publication Number Publication Date
JPH11506904A true JPH11506904A (ja) 1999-06-22

Family

ID=27020105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8528658A Ceased JPH11506904A (ja) 1995-03-21 1996-03-21 Ｒａｇｅ腫瘍拒絶抗原

Country Status (6)

Country Link
EP (1) EP0815229A2 (fr)
JP (1) JPH11506904A (fr)
AU (1) AU705768B2 (fr)
CA (1) CA2211448A1 (fr)
NZ (1) NZ306122A (fr)
WO (1) WO1996029409A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7284598A (en) * 1997-05-05 1998-11-27 Incyte Pharmaceuticals, Inc. Rage1-like protein
JP2001516009A (ja) * 1997-07-17 2001-09-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ガン関連核酸及びポリペプチド
WO1999058546A1 (fr) * 1998-05-13 1999-11-18 Ludwig Institute For Cancer Research Antigene a association tumorale code par le brin antisens d'un nouveau gene a expression ubiquiste
US6686147B1 (en) * 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
EP1117791A2 (fr) * 1998-10-05 2001-07-25 Ludwig Institute For Cancer Research Antigenes associes au cancer et leurs utilisations
AU6282499A (en) * 1998-10-05 2000-04-26 Ludwig Institute For Cancer Research Renal cancer associated antigens and uses therefor
US7338670B2 (en) 2005-04-14 2008-03-04 Duke University Use of an agent that restores tissue perfusion and oxygenation
US20110311448A1 (en) * 2007-11-02 2011-12-22 Ann Marie Schmidt Antibody to rage and uses for in vivo imaging or for targeting therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0658113B1 (fr) * 1992-08-31 2004-10-20 Ludwig Institute For Cancer Research Nonapeptide isole derive du gene mage-3 et presente par hla-a1, et ses utilisations

Also Published As

Publication number Publication date
AU5429896A (en) 1996-10-08
AU705768B2 (en) 1999-06-03
CA2211448A1 (fr) 1996-09-26
WO1996029409A2 (fr) 1996-09-26
WO1996029409A3 (fr) 1996-11-07
EP0815229A2 (fr) 1998-01-07
NZ306122A (en) 1999-06-29

Similar Documents

Publication Publication Date Title
JP3096739B2 (ja) Ｈｌａ分子によって提示される単離ノナペプチドとその使用
US6369211B1 (en) MAGE-3 peptides presented by HLA class II molecules
JP3477523B2 (ja) Ｍｈｃ分子ｈｌａ−ｃ−クローン１０と複合体を形成する分離されたペプチドとその利用方法
JP3608788B2 (ja) Ｍａｇｅ−３遺伝子から誘導されてｈｌａ−ａ１により提示される単離されたノナペプチドおよびそれらの用途
JP3433322B2 (ja) 腫瘍拒絶抗原先駆体をコード化する核酸分子
US5879892A (en) Leukemia associated genes
US5939526A (en) Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof
US7148326B2 (en) Tumor antigen
JPH09504165A (ja) Ｇａｇｅ腫瘍拒絶抗原前駆体の発現を決定する事による疾患診断法
US6013481A (en) Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
JPH10511401A (ja) Ｇａｇｅ腫瘍拒絶抗原をコードする、単離、トランケート核酸分子
JP3721437B2 (ja) 単離チロシナーゼ由来ペプチド抗原とその利用方法
JPH08506100A (ja) Ｈｌａ−ａ２／チロシナーゼペプチド抗原を発現する異常細胞を有する個体の検出と治療
JPH11506904A (ja) Ｒａｇｅ腫瘍拒絶抗原
JP2002502224A (ja) 細胞異常を患う個人を同定するための方法
AU727028B2 (en) Brain glycogen phosphorylase cancer antigen
JP2002509859A (ja) Ｈｌａ−ａ２９分子に結合する単離ポリペプチド、それらをコードする分子である核酸、およびそれらの使用
JPH11509860A (ja) Ｈｌａ−ｂ４４分子によって提示される腫瘍拒絶抗原とその利用方法
AU722111C (en) Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
JPH11505103A (ja) ＭＨＣ分子ＨＬＡ−Ｃｗ▲上★▼１６０１と複合体を形成するペプチドをコードする単離核酸分子とその利用
WO2003104259A2 (fr) Peptides presentes par des molecules hla-b18 et hla-cw16 et utilisations de ces peptides

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040116

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040415

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20040518

A045 Written measure of dismissal of application

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20040928